These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31585703)

  • 1. Paediatric hepatitis C virus infection and its treatment: Present, past, and future.
    El-Shabrawi M; Hassanin F
    Arab J Gastroenterol; 2019 Sep; 20(3):163-174. PubMed ID: 31585703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reinventing HCV Treatment: Past and Future Perspectives.
    Carter W; Connelly S; Struble K
    J Clin Pharmacol; 2017 Mar; 57(3):287-296. PubMed ID: 27654843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regimens for the Hepatitis C Treatment-Naive Patient.
    Ayoub WS; Tran TT
    Clin Liver Dis; 2015 Nov; 19(4):619-27, v. PubMed ID: 26466651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct-Acting Antiviral Agents: Regimens for the Interferon Failure Patient.
    Kushner T; Khungar V
    Clin Liver Dis; 2015 Nov; 19(4):629-39, v-vi. PubMed ID: 26466652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regimens for Patients Coinfected with Human Immunodeficiency Virus.
    Wyles DL
    Clin Liver Dis; 2015 Nov; 19(4):689-706, vi-vii. PubMed ID: 26466656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus protease inhibitor-resistance mutations: our experience and review.
    Wu S; Kanda T; Nakamoto S; Imazeki F; Yokosuka O
    World J Gastroenterol; 2013 Dec; 19(47):8940-8. PubMed ID: 24379619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues.
    Feld JJ
    Curr Drug Targets; 2017; 18(7):851-862. PubMed ID: 26302808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
    Tornai I
    Orv Hetil; 2015 May; 156(21):849-54. PubMed ID: 26038992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New era in the treatment of chronic hepatitis C - novel direct acting antivirals].
    Horváth G; Halász T; Makara M; Hunyady B
    Orv Hetil; 2015 May; 156(21):841-8. PubMed ID: 26038991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors.
    Welzel TM; Dultz G; Zeuzem S
    J Hepatol; 2014 Nov; 61(1 Suppl):S98-S107. PubMed ID: 25443350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct-acting antivirals: the endgame for hepatitis C?
    D'Ambrosio R; Degasperi E; Colombo M; Aghemo A
    Curr Opin Virol; 2017 Jun; 24():31-37. PubMed ID: 28419938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral strategies in hepatitis C virus infection.
    Sarrazin C; Hézode C; Zeuzem S; Pawlotsky JM
    J Hepatol; 2012; 56 Suppl 1():S88-100. PubMed ID: 22300469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
    Welch NM; Jensen DM
    Liver Int; 2015 Jan; 35 Suppl 1():11-7. PubMed ID: 25529082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.
    Götte M; Feld JJ
    Nat Rev Gastroenterol Hepatol; 2016 Jun; 13(6):338-51. PubMed ID: 27147491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
    Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
    Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
    Kowdley KV; Lawitz E; Poordad F; Cohen DE; Nelson DR; Zeuzem S; Everson GT; Kwo P; Foster GR; Sulkowski MS; Xie W; Pilot-Matias T; Liossis G; Larsen L; Khatri A; Podsadecki T; Bernstein B
    N Engl J Med; 2014 Jan; 370(3):222-32. PubMed ID: 24428468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiviral treatment of chronic hepatitis C].
    Berger A
    Med Monatsschr Pharm; 2012 Feb; 35(2):55-60. PubMed ID: 22400430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meet the Classes of Directly Acting Antiviral Agents: Strengths and Weaknesses.
    Chacko KR; Gaglio PJ
    Clin Liver Dis; 2015 Nov; 19(4):605-17, v. PubMed ID: 26466650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of hepatitis C infection. A revolution should not hide another].
    Sogni P
    Presse Med; 2014 Apr; 43(4 Pt 1):339-40. PubMed ID: 24661837
    [No Abstract]   [Full Text] [Related]  

  • 20. Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study.
    Hoffmann L; Ramos JA; Souza EV; Araújo Ramos AL; Villela-Nogueira CA; Urményi TP; Tanuri A; Rondinelli E; Silva R
    Virol J; 2013 Feb; 10():57. PubMed ID: 23409973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.